Arnatar Therapeutics Announces Three Presentations at AASLD The Liver Meeting® 2026

Invited oral presentation highlights ART4, Arnatar’s translation-enhancing antisense oligonucleotide designed to restore JAG1 expression in Alagille syndrome

Additional presentations demonstrate the potential of the ACT-UP1 platform to enhance endogenous HNF4α and FGF21 expression in liver and metabolic diseases

SAN DIEGO, Nov. 2, 2026 -- Arnatar Therapeutics, a clinical-stage biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced that new preclinical data from its proprietary ACT-UP1 antisense oligonucleotide platform will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®2026.

Arnatar will deliver three presentations on November 7,2026, including an invited oral presentation highlighting ART4, the Company’s translation-enhancing antisense oligonucleotide candidate for Alagille syndrome (ALGS), as well as poster presentations demonstrating antisense-mediated enhancement of HNF4α and FGF21 expression in preclinical models of liver and metabolic disease.

“These presentations highlight the potential breadth of our ACT-UP1 platform to selectively increase the expression of therapeutically important endogenous proteins across both rare genetic and prevalent metabolic diseases,” said Xuehai Liang, Ph.D., Chief Executive Officer of Arnatar Therapeutics. “Our work with ART4 demonstrates the potential to directly address JAG1 haploinsufficiency, the underlying genetic cause of most cases of Alagille syndrome, while our HNF4α and FGF21 programs illustrate how the same platform can be applied to larger liver and metabolic indications. We look forward to sharing these findings with the scientific community as we continue advancing a new class of RNA medicines designed to restore protein function.”

Invited Oral Presentation

Title: ART4, a Translation-Enhancing Antisense Oligonucleotide, Restores JAG1 Expression and Improves Liver Disease in Preclinical Models of Alagille Syndrome
Session: Industry Research Showcase
Presentation Type: Abstract Parallel / Invited Abstract Presenter
Publication Number: 0171
Date: November 7, 2026
Session Time: 8:00-9:30 a.m.
Presentation Time: 8:00-8:15 a.m.
Presentation Duration: 15 minutes

Summary: Alagille syndrome is a rare, multisystem genetic disorder most commonly caused by JAG1 haploinsufficiency, resulting in impaired Notch signaling, bile duct paucity, cholestasis, and progressive liver disease. ART4 is a translation-enhancing antisense oligonucleotide developed using Arnatar’s proprietary ACT-UP1 platform to increase expression of endogenous JAG1 protein and directly address the underlying genetic cause of disease.

Arnatar will present preclinical findings demonstrating that ART4 increases JAG1 expression and restores downstream Notch pathway activity. In disease models, increased JAG1 expression was associated with improvements in bile duct architecture and liver disease biomarkers, including bile acids, bilirubin, ALT, and AST. The presentation will highlight the potential of ART4 as a first-in-class, disease-modifying therapeutic approach for patients with Alagille syndrome.

Poster Presentation #1

Title: Antisense-Mediated Upregulation of HNF4α Improves Liver Fibrosis in Preclinical Models of MASH and Toxin-Induced Liver Injury
Session: MASLD/MASH - Therapeutics: New Agents and Approved/AvailableAgents
Presentation Type: Abstract Poster
Publication Number: 3542
Date: November 7, 2026
Presentation Time: 1:00-2:00 p.m.

Summary: Hepatocyte nuclear factor 4 alpha (HNF4α) isa master transcriptional regulator of hepatocyte identity and metabolic function. Reduced HNF4α activity has been associated with hepatocyte dysfunction and the progression of chronic liver disease and fibrosis.

Arnatar will present preclinical data demonstrating the potential of ACT-UP1 antisense oligonucleotides to enhance endogenous HNF4α expression and improve liver fibrosis across models of metabolic dysfunction-associated steatohepatitis (MASH) and toxin-induced liver injury. These findings support further evaluation of HNF4α upregulation as a potential therapeutic strategy for chronic liver disease.

Poster Presentation #2

Title: Novel Antisense Oligonucleotides Enhance Endogenous FGF21 Expression and Ameliorate Dyslipidemia and Hepatic Steatosisin Preclinical Metabolic Disease Models
Session: MASLD/MASH - Therapeutics: New Agents and Approved/AvailableAgents
Presentation Type: Abstract Poster
Publication Number: 3538
Date: November 7, 2026
Presentation Time: 1:00-2:00 p.m.

Summary: Fibroblast growth factor 21 (FGF21) is anendogenous metabolic hormone involved in the regulation of lipid and glucosemetabolism and has emerged as an important therapeutic target across metabolicand liver diseases.

Arnatar will present preclinical data demonstrating the use of novel antisense oligonucleotides to enhance endogenous FGF21 expression. In preclinical metabolic disease models, FGF21 upregulation was associated with improvements in dyslipidemia and hepatic steatosis. The findings further demonstrate the versatility of the ACT-UP1 platform to increase therapeutically relevant endogenous proteins and expand the potential application of translation-enhancing RNA medicines to cardiometabolic and liver diseases.

About Arnatar Therapeutics

Arnatar Therapeutics is a clinical-stage biotechnology company redefining the possibilities of RNA medicine. Through its proprietary DARGER™ platform, Arnatar integrates siRNA-mediated gene silencing with its first-in-class ACT-UP1 antisense oligonucleotide technology designed to enhance endogenous protein expression. This dual-modality approach enables Arnatar to develop programmable RNA medicines that either suppress harmful disease drivers or restore insufficient protein function.

Arnatar is advancing a pipeline of RNA therapeutics across liver, kidney, cardiometabolic, rare genetic, and other diseases with significant unmet medical need. Founded by leaders in RNA therapeutics and backed by leading biotechnology investors, Arnatar is committed to translating innovative RNA science into transformative medicines for patients.

Contacts

Jason Shieh

Business Development

bd_partnering@arnatar.com